Zhang Wen, Shi Qun, Wu Dong-hai, Bao Chun-de, Yang Nan-ping, Li Zhan-guo, Zhu Ping, Zhang Xiao, Huang Ci-bo, He Dong-yi, Ye Zhi-zhong, Tao Yi, Fang Yong-fei, Gu Jie-ruo, Wu Hua-xiang, Sun Ling-yun, Yang Xiu-yan, Huang Feng, Xu Hu-ji, Zhao Dong-bao, Zhang Miao-jia, Zheng Yi, Ai Mai-xing, Lu Jun, Zhang Feng-chun
Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi. 2009 Jul 21;89(27):1876-80.
To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA).
Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated.
After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient' s global assessment, and physician's global assessment before and after therapy.
Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.
探讨英夫利昔单抗（IFX）联合甲氨蝶呤（MTX）治疗类风湿关节炎（RA）患者的疗效及安全性。
前瞻性观察采用MTX与IFX联合治疗的难治性RA患者。IFX以3mg/kg的剂量在第0、2、6周输注，之后每8周输注一次。治疗期间，评估临床变量、疾病活动度及不良反应。
治疗后，分别有69.8%、52.4%、29.5%和7.2%的RA患者达到美国风湿病学会（ACR）20、ACR50、ACR70和ACR90标准。治疗前后关节肿胀计数、压痛关节计数、视觉模拟评分（VAS）、患者整体评估及医生整体评估的变化有显著统计学差异。
英夫利昔单抗联合MTX治疗难治性RA患者疗效显著且安全性良好。
